Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Programmed death-ligand 1 (PD-L1) is a key immune checkpoint molecule.
• PD-L1 interaction with programmed death-1 (PD-1) inhibits T cell responses.
• Current therapies targeting PD-L1 involve antibodies disrupting this interaction.

Purpose of the Study:

• To investigate a novel mechanism for inhibiting PD-L1.
• To explore small molecule-induced dimerization and internalization of PD-L1.
• To evaluate the therapeutic potential of this approach in cancer and viral infections.

Main Methods:

• Development of small molecules to induce PD-L1 dimerization and internalization.
• Testing in a humanized mouse model of colorectal cancer.
• Assessment of immune cell responses in patients with chronic hepatitis B.

Main Results:

• Small molecule-induced PD-L1 inhibition significantly reduced tumor size in a colorectal cancer model.
• This approach promoted T cell proliferation.
• Antigen-specific T and B cell responses were elevated in chronic hepatitis B patients treated with the inhibitor.

Conclusions:

• Small molecule-induced PD-L1 internalization offers a new strategy for checkpoint inhibition.
• This mechanism differs from antibody-based therapies.
• The approach demonstrates therapeutic potential for both oncology and chronic viral infections.